Amgen EVP reports small tax-withholding share disposition

Amgen Inc. EVP of Research and Development James E. Bradner reported a small tax-related share disposition.

Rhea-AI Filing Summary

Amgen Inc. EVP of Research and Development James E. Bradner reported a small tax-related share disposition. On the reported date, 446 shares of common stock were withheld at $331.11 per share to satisfy tax obligations, a non-market transaction classified as a tax-withholding disposition.

After this event, Bradner directly held 30,016 Amgen shares. The reported holdings include 1,273 dividend equivalents tied to unvested restricted stock units that will pay out in Amgen common stock as they vest, along with cash for any fractional share amounts.

Insider Trade Summary

Exercise Price or Tax Liability: 446 shares

Exercise Price or Tax Liability 1 txn

Insider Bradner James E.

Role EVP, Research and Development

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	446	$331.11	$148K

Holdings After Transaction: Common Stock — 30,016 shares (Direct)

Footnotes (1)

1. F1. These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

Tax-withholding shares: 446 shares Withholding price: $331.11 per share Post-transaction holdings: 30,016 shares +1 more

4 metrics

Tax-withholding shares 446 shares Common stock withheld to cover tax liability

Withholding price $331.11 per share Value used for tax-withholding disposition

Post-transaction holdings 30,016 shares Direct Amgen holdings after transaction

Dividend equivalents included 1,273 DEs Credits tied to unvested restricted stock units

Key Terms

Dividend Equivalents (DEs), Restricted Stock Units, Equity Incentive Plan, tax-withholding disposition

4 terms

Dividend Equivalents (DEs) financial

"These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

tax-withholding disposition financial

"transaction_action: tax-withholding disposition"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) report for James E. Bradner?

Amgen reported that EVP of Research and Development James E. Bradner had 446 shares withheld as a tax-withholding disposition. This non-market transaction covered tax obligations and did not represent an open-market purchase or sale of Amgen common stock.

How many Amgen (AMGN) shares were involved in Bradner’s tax-withholding transaction?

The transaction involved 446 shares of Amgen common stock withheld at $331.11 per share. These shares were used to satisfy tax liabilities related to equity compensation, rather than being sold on the open market to outside investors.

How many Amgen (AMGN) shares does James E. Bradner hold after this Form 4 filing?

Following the reported tax-withholding disposition, James E. Bradner directly holds 30,016 shares of Amgen common stock. This figure includes dividend equivalents associated with unvested restricted stock units that will deliver Amgen shares as those awards vest over time.

What are dividend equivalents (DEs) mentioned in the Amgen (AMGN) Form 4 footnote?

Dividend equivalents are credits tied to unvested restricted stock units that mirror dividends on Amgen stock. In this filing, 1,273 DEs are included and will be paid out as shares of Amgen common stock based on the vesting schedule, plus cash for fractional amounts.

Was the Amgen (AMGN) insider transaction an open-market sale or a tax withholding?

The filing classifies the event as a tax-withholding disposition, not an open-market sale. Shares were delivered to cover tax liabilities on equity awards, meaning they were not actively sold into the market by James E. Bradner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 07:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradner James E.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research and Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		F		446	D	$331.11	30,016(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ James E. Bradner	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)